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Introduction 
Dengue fever (DF) is endemic in many South East Asian countries. It is 
caused by one of the four types of dengue virus, which is spread by Aedes 
aegypti mosquito. An estimated 2.5 to 3 billion people are at risk of acquiring 
this illness worldwide. Five lakhs of DHF require hospitilization each year, of 
which 90% are children, less than 15 age. The recent major epidemics in South 
East Asia regions occurred in India, Sri Lanka, Thailand, Myanmar and 
Indonesia. The number of cases have increased over the last 3-5 years with 
recurring epidemics and increasing incidence of DHF and DSS(1). The factors 
implicated for the increasing incidence in these epidemics are not fully 
understood. Unprecedented global population growth and unplanned 
urbanization in tropical countries has been the root cause for the spread of these 
epidemics. This has lead to poor housing standards, overcrowding and 
deterioration of water, sewer and waste management systems. There has also 
been increase in the air travel providing the ideal mechanism for spread of the 
virus across the major continents. 
                    Broadly, the management of these cases involves segregating them 
into those with the milder forms of disease, dengue fever from dengue 
hemorrhagic fever, which may progress rapidly to shock, multiorgan 
dysfunction and death. Recognition of capillary leak, which forms the defining 
factor for the serious form of this infection, becomes very important in the 
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management of these cases. If untreated, mortality from the complications of 
DF is as high as 20% whereas if recognized early and managed properly, 
mortality is less than 1%. 
             The present study analyses the frequency and degree of hepatic 
dysfunction in children < 15yrs admitted with dengue infection. The severity of 
liver dysfunction in affected children by DI varies from mild injury with mild 
elevation of transaminases activity to very severe injury presenting with 
jaundice (32-34) 
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REVIEW OF LITERATURE 
Dengue infection is the most common mosquito –borne viral disease of humans 
that it has become a major international public health care in recent years. The 
incidence has increased 30 fold in last 50yrs, geographically expanding to other 
countries as shown in the fig 1.11. 
 
CHAPTER 1 
Figure 1.1 Countries/areas at risk of dengue transmission, 2008 
Data Source: World Health Organization Map 
Production: Public Health Infrmation and Geographic 
Information Systems (GIS) World Health Organization 
The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever 
on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, 
or concerning the delimitation of its frontiers or boundaries. Dotted lines or maps represent approximate border lines for which 
 
Around 50 million dengue infections occur every year and approximately 
2.5 billion people live in dengue endemic countries (1). The global incidence of 
dengue has increased abruptly in recent decades (1, 2). In 1905 Bancroft identified 
the vector for dengue as aedes aegypti (3). The isolation of dengue virus type 1 
& 2 in 1943 and 1944 marked the modern era of dengue research. The 
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etiological agent for dengue was found in human blood by Craig and Askburn 
(4)
.Many epidemics have been reported since virus was isolated in 1945 (5, 6, 7, 8, 9, 
10)
. Dengue infection is an endemic in more than 100 countries in Africa, 
America, Southeast Asia, West pacific and Eastern Mediterranean. Nearly > 
70% population worldwide at risk of dengue, live in member states of WHO, 
Western pacific region and South East Asia region bearing nearly 75% global 
burden of the disease(1). The first epidemic was recorded in the Chinese 
encyclopaedia of diseases, symptoms, and remedies written during Chin 
dynasty (265- 420 AD), edited in 610 AD (Tang dynasty) and in 992 AD 
(Northern sung dynasty). The Chinese first called the disease as water poison 
and thought it was spread by flying insects (11). In Manila it was called 
Philippine hemorrhagic fever in 1954 (12).By 1970, 9 countries had experienced 
dengue epidemics. Since 2000, epidemic has spread to new areas and in 2003, 8 
countries reported dengue cases (1). In 2005 WHO’s Global Outbreak Alert and 
Response Network (GOARN) responded to an outbreak in Timor –Leste with a 
high case fatality rate (1). The number of dengue infections reported to WHO up 
to 2007 is shown in fig 1.2 
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Nearly 5, 00,000 people with dengue fever require hospitalisation every year 
majority being children. Nearly 2.5% of them die without proper treatment. 
Proper treatment at the appropriate time can reduce death rates to < 1%. 
Dengue in our country 
First case of dengue fever was reported from Vellore district (Tamil 
Nadu) in 1956. Calcutta in West Bengal reported the first DHF during an 
outbreak with 30% cases showing hemorrhagic manifestations. All the 4 
serotypes of dengue -1, 2, 3, 4 have been isolated in India. The major outbreak 
in Delhi was in 1988 and then in 1996   (5, 6, 13, 14). Dengue cases have been on the 
rise since 1997 in Tamil Nadu (15). An epidemic was reported from Chennai 
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during September 2001 & 2002 with majority of the children being less than 5 
years (16, 17). 
Dengue virus 
                 Dengue virus (DEN) is a small single stranded RNA virus with four 
different serotypes (DEN 1-4) belonging to genus Flavi virus and family 
Flaviviridea (1). The Flavi virus is small with a lipid envelope and is spherical in 
shape. Though all 4 serotypes are antigenically similar; they differ to elicit cross 
protection only for a few months. Infection with one dengue serotype gives life 
long immunity to that virus serotype only. 
  The Vectors  
                   The DEN virus is transmitted to humans only when an infected 
Aedes aegypti takes a blood meal. They are seen in both tropical and subtropical 
areas widely distributed mostly between latitudes 35⁰ N and 35⁰ S (1). They are 
not seen in high altitudes. The female mosquito lays eggs on damp surfaces 
above water line. Under optimal conditions the aquatic stage can be as short as 
7 days. The eggs can survive without water for 1 year. The adult survival is an 
average of 15 days. Their survival is longer during rainy season and the risk of 
virus transmission is greater. They are typically daytime feeders and have to 
feed on many people to complete one full meal there by infecting them all. 
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The Host  
                       Infection by any of the 4 serotypes after an incubation period of 
4-10 days produce wide spectrum of illness though most infections are 
asymptomatic or subclinical (1). Travel to dengue epidemic area is an important 
risk factor. Individual risk factors like age, secondary infection, ethnicity and 
possibly chronic diseases determine the severity of disease. Young children are 
at greater risk of dengue shock because their ability to compensate for capillary 
leakage is much less when compared to adults. 
  Environmental factors 
                          The mosquito’s life span is influenced by temperature and 
humidity. They survive best between a temperature of 16 – 30 degrees and a 
relative humidity of 60 -80%. Rainfall and water storage influences their 
population.  
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Transmission cycle 18, 19, 20 
 
Aedes aegypti gets infected with the dengue virus when the female species of 
the mosquito takes a blood meal from a person in his acute febrile phase of 
illness (viremia). After 8 to 10 days which is the incubation period, the 
mosquito gets infected and transmits the dengue virus into the next person while 
taking a blood meal. There is also evidence of trans ovarian transmission where 
there is evidence of vertical transmission from infected mosquitoes to the eggs. 
Maximum blood meals are taken during early morning and in afternoons. For one complete meal a 
female Ae. aegypti feeds on several people infecting them all. After a person has been bitten the 
virus has an incubation period of 4 to 7 days following which the infected person develops acute 
onset of fever along with many non-specific signs and symptoms 21. The infected dengue virus will 
continue to circulate in the peripheral blood 22.When another female mosquito takes the meal from 
the infected person during his viraemic stage, that mosquito also gets infected and thereby 
transmits virus to another uninfected person after an incubation period of 8 to 10 days 16, 18. 
Pathophysiology and pathogenesis 
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Pathogenesis of DHF is not fully understood but 2 Patho physiological 
changes suggested are (1)  
a) Increased vascular permeability resulting in plasma leakage, 
hypovolemia and shock and  
b) Abnormal haemostasis due to vasculopathy , thrombocytopenia and 
coagulopathy leading to various hemorrhagic manifestations .The causes for the 
above changes are not clear. 
 Two theories put forth are (11):   
 Immune enhancement hypothesis   - says that patients with a secondary DI 
with a heterologous DEN serotype have increased risk of developing severe 
dengue. 
The 2nd hypothesis says that DEN virus vary and change genetically like 
all animal viruses where increased virus replication and viraemia are the forms 
of phenotypic expression. 
Differential diagnosis of dengue fever 
Chicken gunya 
Rubella 
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Coxsackie infections 
Infectious mononucleosis 
Influenza 
Leptospirosis 
Rickettsial infections 
Differential diagnosis of severe dengue 
Chicken gunya 
DIC with gram negative sepsis 
Kawasaki disease 
Leptospirosis 
Meningococcal sepsis 
 
Classification of dengue 
Dengue fever 
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         Dengue fever can occur in both primary and secondary infections. The 
onset is abrupt with high grade fever along with other features like abdominal 
discomfort, myalgia, arthralgia, anorexia, severe headache and occasionally 
maculopapular rash. The fever pattern is usually biphasic and lasts 2 to 7 days23. 
Coryza and flushed appearance are the other commonly observed features in 
young children whereas vomiting, headache and abdominal are less commonly 
seen. Bleeding manifestations are minimal in dengue fever though purpura, 
epistaxis, petechiae and gingival bleeding have been reported in some 
individuals 24. Complications in dengue fever are very minimal and most of 
them recover uneventfully. 
Dengue haemorrhagic fever 
                   DHF is usually seen in secondary dengue infections but can also 
occur in primary infections especially in infants. The fever pattern then again is 
similar to dengue fever lasting for 2 to 7 days. Once the temperature drops to 
normal levels the patient may either completely recover or develop plasma 
leakage. Those children who remain sick after the fever crashes are the ones 
who have a high chance of developing DHF. In those children with DHF 
defervescence usually occurs between day 3 and 4 25. Plasma leakage sets in 
within 24 to 48hrs after the onset of DHF with clinical signs of hypotension and 
tachycardia. Severe plasma leakage results in circulatory disturbances like 
narrow pulse pressure prolonged capillary refill time and may even cause shock. 
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Ascites and pleural effusion are the other common manifestations of plasma 
leakage. Very rarely has pericardial effusion been reported and is associated 
with high morbidity and mortality. Bleeding manifestations are usually seen 
once the fever has subsided 26. The most common site of bleeding is the GI tract 
and is usually manifested in the form of hematemesis or malena. The recovery 
is usually fast and return of appetite is a good sign of recovery. 
Dengue shock syndrome 
                 DSS is the most severe form of dengue infection and has a very high 
mortality rate. There is often severe plasma leakage resulting in circulatory 
disturbances, circumoral cyanosis and cold peripheries. Persistent vomiting and 
acute abdominal pain are the early danger signs of impending shock. Sudden 
fall in blood pressure may indicate a profound shock27. Profound shock may 
result in metabolic acidosis which could precipitate disseminated intravascular 
coagulation resulting in massive bleeding. DSS could result in dengue 
encephalopathy which could be triggered either by metabolic or electrolyte 
disturbances.  
 
Case definition 
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Dengue fever -   Fever usually lasts 2 to 7 days and has 2 or more of the 
following feature: 
Headache  
Rash 
Bleeding manifestations 
Leukopenia  
Myalgia or arthralgia 
Dengue hemorrhagic fever- Criteria includes a serologically confirmed 
dengue infection with one or more of following hemorrhagic tendencies: 
Positive tourniquet test 
Petechiae, ecchymoses or purpuric spots 
Platelet value less than 1, 00,000 
 
 
 
Newer classification 
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1. Dengue fever:            
Live in/ travel to endemic area, 
Fever + 2 of following criteria: 
Nausea, vomiting, rash, aches and pain positive tourniquet 
test,thrombocytopenia < 1 lakh and any warning signs . 
The warning signs are: Abdominal pain / tenderness, Persistent vomiting, 
Clinical fluid accumulation, mucosal bleed, Lethargy, restlessness, Liver > 2 cm 
palpable, Increase in hematocrit with rapid fall in platelet. 
2. Severe dengue 
Severe plasma leakage leading to shock, fluid accumulation with respiratory 
distress  
Severe bleeding  
Severe organ involvement - increased SGPT / SGOT, impaired consciousness 
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 Course of dengue illness 
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Febrile phase 
 
Develops high grade fever suddenly ,Lasts 2- 7 days accompanied by facial 
flushing , skin erythematic , generalized body aches , myalgia , arthralgia and 
headache. Anorexia, nausea and vomiting are common. Positive tourniquet test 
increases possibility. Petechiea and mucosal bleeds may be seen. Massive 
vaginal bleed/ GI bleed may occur but not common .Liver is often enlarged and 
tender. 
Critical phase 
 
Around time of defervescence, temperature drops to normal or less; usually 3 
– 7 days of illness. 
There is increase in capillary permeability in parallel with a increase in 
hematocrit. 
Clinically significant plasma leakage lasts 24 – 48 hours. 
Progressive leucopenia followed by decrease in platelet count usually 
precedes plasma leakage. 
Patients without an increase in capillary permeability will improve while 
those with become worse as a result of lost plasma volume. 
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Degree of increase in hematocrit above baseline reflects severity of plasma 
leakage. 
Pleural effusion and ascites occurs depending on degree of plasma leakage 
and volume of fluid therapy. 
Shock occurs when critical volume of plasma is lost through leakage. 
Prolonged shock results in organ impairment, metabolic acidosis and DIC 
leading to severe hemorrhage causing hematocrit to decrease in severe 
shock.  
Recovery phase 
 
After 24 – 48 hrs of critical phase; gradual re -absorption of extra vascular       
compartment takes place in following 48 – 72 hrs 
Features:  
General well being improves 
Appetite improves 
GIT symptoms abate 
Hemodynamic status stabilizes and diuresis ensues  
Bradycardia  
Some experience generalised pruritis  
PCV stabilizes 
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Leucopenia starts to rise  
Platelet count increases 
Respiratory distress from massive pleural effusion or ascites will occur if 
excessive fluid is administered. 
Laboratory diagnosis 
Criteria for laboratory diagnosis: one or more of the conditions below 
The virus should be isolated from plasma, serum, leucocytes or autopsy sample. 
Four fold or higher rise in reciprocal IgG or IgM antibody titres to one or more 
of the dengue viral antigens. 
Dengue viral antigens demonstrated in serum samples by ELISA or in autopsy 
tissue by immune histochemistry. 
Dengue viral genomic sequence detected by PCR in autopsy tissue and serum 
sample. 
The gold standard for diagnosis of dengue infection is isolation of the virus and 
the second best alternative is to confirm by serology. The serological tests 
available are: 
Hemagglutination test (HI) 
Compliment fixation test and neutralization test 
MAC ELISA IgM immunosorbent assay and indirect IgG ELISA 
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SEROLOGICAL DIAGNOSIS 
IGM ELISA 
The test is based on detecting dengue specific IgM antibodies in the 
serum and to capture them using anti-human IgM. This is a very simple rapid 
test and requires very minimal sophistication. For easy detection an enzyme 
substrate is added to give colour to the reaction. 80% of patients in primary 
dengue infection show IgM antibodies by day 5 and 99% within 20days. The 
IgM antibodies peak at 2wks and come down over the next 2 to 3 months. In 
secondary dengue IgM response is low and slow and some patients might not 
even show detectable IgM. 
 
 IgG ELISA 
          Primary dengue infection can be distinguished from secondary dengue 
using an indirect IgG ELISA by comparing with IgM. This test is non-specific 
and shows same broad cross reactivity among Flavi virus and cannot be used to 
identify the dengue serotype. In primary dengue IgG rise later and gradually 
decline to lower level which persists for life. In secondary dengue infection the 
IgG response is rapid and is much higher when compared to the response in 
primary dengue. The IgG value peaks at 2 weeks and slowly comes down over 
3 to 6 months. 
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The IgG and IgG serology is relatively inexpensive and is simple to 
perform33. The test has good sensitivity and can be done real quickly. The IgM 
ELISA has a sensitivity of 84% -98.5% and a hundred percent specificity39. 
Ideally both the serological tests should be performed during the acute as well 
as convalescent period but for cost reasons and difficulty of revisit, only one 
sample is sent after 5 days of illness. 
 
Other tests available 
Hemagglutination inhibition test (HI) test 
 
In the past this was the most widely used method for serological 
diagnosis. The limitations of this method were extensive cross-reactions, time 
consuming and need for repeated samples during both acute and convalescence 
period. 
Compliment fixation test 
 
This test is not routinely done nowadays .This test requires highly trained 
people and reagents which are thermolabile which makes it all the more 
difficult. 
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Rapid diagnostic test 44, 45, 46 
 
                     A lot of commercial kits for rapid diagnosis are available in the 
market. Though we get the results within 15 to 20 mins, WHO GUIDELINES 
have not recommended this test to guide management of dengue. 
PCR technique 47, 48 
 
                   In dengue PCR gives a rapid and serotype specific diagnosis. This 
test is simple, sensitive and reproducible if well controlled. 
Management: 
3 groups  
Group A – These patients can be sent home, these patients are able to take 
adequate oral feeds, pass urine at least once in 6hrs and have no warning signs. 
 GROUP B – they require in hospital management. These are patients with 
warning signs.  
Obtain an urgent hematocrit and start isotonic solutions such as 0.9% saline, RL 
or Hartmann’s solution. 
Start with 5- 7 ml/kg/hr for 1- 2 hrs  
                            ↓ 
 Reduce to 3- 5 ml/kg/hr for 2 – 4hrs 
                             ↓   
 Decrease to 2 – 3 ml/kg/hr or less  
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Reassess the clinical status and repeat hematocrit value. If hematocrit 
remains same or rises only minimally; continue with same  rate of fluids [ 2- 3 
ml/kg/hr].If vital signs are worsening and hematocrit value is rising rapidly , 
increase rate to 5 – 10 ml/kg/hr for 1-2hrs.Reassess clinical status and repeat 
hematocrit value and review fluid infusions accordingly .Continue with 
minimum fluids to maintain good perfusion and urine output.Iv fluids are 
needed only for 24-48hrs.Decrease the rate of fluids when plasma leakage 
decreases towards end of critical phase . 
Group c 
 
In cases of severe plasma leakage leading to shock / fluid accumulation 
with respiratory distress, Severe hemorrhages, Severe organ impairment 
[hepatic damage, renal impairment, cardiomyopathy , encephalopathy / 
encephalitis].  
The goals of treatment should be: Improving central and peripheral 
circulation, decreasing tachycardia , improving BP & pulse volume, warm and 
pink extremities, CRT < 2 sec, Improving end organ perfusion, stable conscious 
levels and to maintain an urine output more than or equal to 1ml/kg/hr.  
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Hepatic dysfunction in dengue 
 
Liver involvement is seen in children with dengue (28-30). Dengue virus 
though not a hepatotoxic virus, many cases of liver injury due to DI has been 
described since 1960 (31). The severity of liver dysfunction in affected children 
by DI varies from mild injury with mild elevation of transaminases activity to 
very severe injury presenting with jaundice (32-34). A direct viral effect or a 
consequence of deregulated host immune response against the virus could be 
the reason for liver dysfunction (35). Pathological  changes in the portal tract like 
centrilobar necrosis, fatty changes and monocyte infiltrations have been 
reported(36).Varying abnormalities of liver enzymes are seen in symptomatic 
dengue patients but their recovery is also soon (Pancharoen et al 2002).Severity 
of liver dysfunction depends on the type of DI and is more common in patients 
with severe dengue. Even in children the ones with severe dengue has been 
reported to have profound liver involvement (28,37).Recent Studies from Thailand 
and India shows that the most important cause of acute hepatic failure in 
children is DI contributing to 34.3% and 18.5% (38,39 ). 
The hepatic dysfunction in DI is shown to have a close association with 
the severity of the disease. Higher levels of liver injury are a good positive 
predictive factor for development of severe dengue (40). Studies have shown that 
there is more than a 10 fold rise in transaminases of children when compared to 
adults (41, 42); this clearly states that children are at higher risk of liver injury than 
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adults. Study done in Lady Hardinge medical college, New Delhi of 61 children 
showed that SGPT and SGOT were elevated in 80 – 87%. A similar study in 
JSS medical college, Mysore showed that 17.27 % of children had more than 10 
fold rises in transaminases levels .The SGPT values were elevated in 69.4 % of 
patients with dengue fever and 92% with severe dengue. There were 82.2% of 
children who had elevated levels of SGPT in a study of 270 patients done by 
Kuo et al in 1992. Mohan et al in 2000 studied 61 children in which 96% had 
elevated SGPT levels in the severe dengue group. During an epidemic in Brazil 
in 2004 Souza et al found that 45% of the cases in a study group of 1585 were 
found to have a higher SGPT levels.  
The patho physiology of liver injury in DI is not clear. Few mechanisms 
suggested were (43). 1) Host immune response system killing virus infected cells. 
2) The virus having a direct cytopathic effect. 3) Shock and hypotension having 
a non specific effect. Gholson et al in 1990 in his Studies showed that SGOT 
levels are much more elevated than SGPT levels .The reason suggested was due 
to excessive release of SGOT from damaged monocytes during DI (Chung et al; 
1992). Since SGOT has a shorter life span of 12.5-22h when compared to SGPT 
which has a life span of 32-43 hrs; the raised SGOT levels normalise much 
faster than the SGPT levels.(hawker 1991) 
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There are a few authors who suggested that drugs like acetaminophen and 
anti emetics taken during the febrile phase potentiate the liver damage ( Suvatte 
et al 1990). 
Though liver size has no connection whatsoever with the severity of 
disease; hepatomegaly is more frequently seen in children in shock when 
compared to non-shock cases (44). Study in JSS medical college reported 79% of 
110 cases with hepatomegaly. Faridi and Petdachai et al had reported 100% 
hepatomegaly in their study group. Isolation of the dengue virus from the liver 
has been done in fatal cases. Similar findings were seen by Burke et al in 1968, 
Sumarmo et al in 1983 and by Rosen et al in 1989. Huerre et al , Rosen et al and 
Bhamarapravati et al found liver to be the main organ where the dengue virus 
was isolated. Using immunohistochemistry, in situ PCR technique and in situ 
hybridization, dengue virus antigens and nucleic acid has been recovered from 
liver tissue though no studies have shown whether viral multiplication happens 
in hepatocytes or not ( 45- 47).Contradicting this Huerre et al in 2004 says that 
DEN virus replicates in Kupffer cells and hepatocytes. Marianneau et al says 
though the DEN enters Kupffer cells effectively, their replicate infective 
capacity is not very efficient. Rosen et al says in his study that DEN 2 or 3 were 
isolated in 5 out of 17 cases using mosquito inoculation technique. Studies have 
shown that specific CD4+ and CD8+ T cells play a major role in the 
pathogenesis of severe dengue forms.  
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SERUM GLUTAMIC PYRUVIC TRANSAMINASE: 
It is also known as Alanine transaminase is an enzyme that when elevated 
suggests hepatocellular injury or inflammation.  
It also occurs in small amounts in cardiac muscle, skeletal muscle and in 
kidney but is much more specific to the liver than aspartate transaminase. 
The most marked rises of both alanine transaminase and aspartate transaminase 
levels may occur with acute hepatocellular injury. 
SGPT is elevated in any hepatitis (A,B,C) , toxin exposure , medications ( 
anticonvulsants , Isotretinoin , rantidine, cimetidine, isoniazid and statins ),non-
alcoholic fatty liver disease and blunt trauma. 
Normal range varies from laboratory to laboratory and we considered 
taking 10 – 40 IU/L as normal value according to our lab. 
 
PROTHROMBIN TIME 
It measures the activation of clotting by tissue factor in presence of 
calcium. 
It is elevated in conditions with deficiency of clotting factors involved in 
extrinsic pathway and deficiency of vitamin K due to intestinal malabsorption 
(cholestasis) or due to intake of vitamin K. 
Normal Prothrombin time is 10 to 13 seconds. 
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Prothrombin time has been standardized using the International 
normalised ratio (INR) so that values can be compared from one laboratory or 
instrument to another. 
This ratio is used to determine similar degree of anticoagulation with 
warfarin like medications. 
 
Activated partial thromboplastin time: 
It measures the intrinsic pathway. 
The measurement of partial thromboplastin time as performed in lab is 
actually “activated” partial thromboplastin time. This test measures the 
initiation of clotting at the level of factor XII through sequential steps to the 
final clot end point. 
It does not measure factor VII, factor XIII or anticoagulants. 
PTT uses a contact activator (silica, kaolin, or ellagic acid) in the 
presence of calcium and phospholipid. Because of the differences in the 
reagents & lab instruments normal range for PTT varies between one hospital 
laboratory and another. 
Normal ranges of PTT are much more variable from lab to lab than in the 
case of PT. 
Our lab normal value is from 24 to 35 seconds. 
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Aim 
 
To asses the frequency and degree of hepatic dysfunction in children less 
15yrs admitted with dengue infection as patients in PSG hospitals. 
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Materials and Methods 
 
Type of study  :  Prospective  cohort  study  
Place of study  :  PSG Institute of Medical Sciences And  
                                            Research, Coimbatore.             
 Study population : Children in age group > 0 – 15 yrs 
                                      Both Sexes 
                                           Only   children with   serologically  proven   
                                           Dengue   infection  were included. 
Period of study     : 1 year (July 2011 – July 2012) 
 
Inclusion criteria  
 
All children who were admitted with serologically proven Dengue 
infection between the age group 0 – 15yrs were included in the study. 
 
Exclusion criteria 
 
                 Chidren with history of chronic liver disease. 
                      Those who are on hepatotoxic drugs. 
                      Children with pre-existing chronic infections. 
                      Children who are potential hepatotoxins. 
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                                     Method  
 
         All children between the age group 0-15 years admitted for clinically 
suspecting dengue infection and later serologically proven dengue (ELISA IgG 
and IgM) were included in the study. The study period was between One year 
(July 2011 – July 2012)  and 136 consecutive samples were included in the 
study based on inclusion criteria. Informed consent was obtained and detailed 
history taken from the parents. Ethical committee approval from PSG Hospitals 
was obtained. All the 136 children underwent investigations according to the 
hospital’s dengue protocol and requirement of the study. The investigations 
done were complete blood count showing total and differential count, 
haemoglobin, hematocrit, platelet and ESR values. Other investigations done 
were SGPT, PT, APTT, dengue serology and chest X ray based on the clinical 
picture. Dengue serology was done on the 7th day after onset of disease. Platelet 
and SGPT values were repeated on a regular basis during the hospital stay 
depending on the clinical status of the patient. From all the serologically proven 
dengue cases with elevated ALT levels, blood samples were obtained to rule out 
other causes of liver injury. Hepatitis A, B and E were ruled out from all the 136 
children included in the study. Ceruloplasmin levels could not be done because 
of the financial limitation of the study. Management of the children were left to 
the respective treating units. Children with elevated SGPT values at discharge 
were asked to repeat the test at 2 weeks.  
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For comparison purposes the total of 136 children were divided into 3 
groups based on their ALT value. The first group was  the group with a normal 
ALT values ( SGPT<40IU/L). The second group was the 2 with slightly 
elevated ALT values (ALT between  40-100IU/L). The third group had ALT 
>100 and was group 3. 
          The complete data regarding patient details along with history, platelet, 
ALT, PT, APTT, hepatomegaly, transfusions required, duration of hospital stay 
and PICU stay, repeat SGPT values, type of dengue and complications if any 
were collected in a pre formed proforma  (Annexure). The formulated data was 
analysed statistically and co relation between the 3 groups with regard to 
symptomatology and lab parameters were assessed.  
Statistical tools used 
                            The data collected from the patients were first edited and 
tabulated. Microsoft Excel has been used to generate graphs, tables etc. 
Diagrammatic representations like bar diagram, pie diagrams are used to 
identify the contribution of different attributes in the thesis. 
Descriptive data was analyzed using mean, median, range and percentage. 
The level of significance noted by 
                 Significant (p value: 0.01<p≤0.05) 
                Strongly significant (pvalue: p≤0.01) 
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Results on continous measurements are presented on mean +_SD (Min-
Max) and results on categorical measurements are presented in number (%). 
Appropriate descriptive and inferential statistics were computed by means of 
SPSS software. Statistical independent t-test analysis was used for 
interpretation. 
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Results 
There were a total of 136 children with serology proven dengue infection 
during the study period. There were 87 boys and 49 girls included in the study.  
 
Age Distribution: Table 1 shows the age distribution of the patients. There 
were 20 children less than 1 year of age, 28 children between 1 to 5 years of 
age, 37 children between 5 to 10 years of age and 40 children of age between 10 
to 15 years. Out of these, 17 out of the 20 children (85%) below 1 year of age 
had elevated ALT, compared to 20 of 28 (71%) in the 1 -5 age group, 37 of 48 
(77%) in the 5-10 age group and 24 of 40 (60%) in those over 10 years. 
 
Table 1: ALT levels in different Age groups  
   Age distribution Normal ALT ALT 40-100 ALT >100 Total no & % with 
elevated ALT 
  <  1 yr        3         7        10 17/20 (85%) 
 1-5   yrs        8         10        10 20/28 (71.4%) 
 5-10 yrs       11         25        12 37/48 (77%) 
10-15 yrs       16         14        10 24/40 (60%) 
 
 
 Figure 1: ALT levels in different Age groups
Sex Distribution: There were 87 males and 49 females. While 58 of the 87 
males had elevated ALT (67%), 40 of the 49 females had elevated ALT 
(81.6%). (Table2) 
Table 2: Association of ALT levels in both the sexes.
ALT level 
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Elevated 
Total 
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 Figure 2: Association of ALT levels in both the sexes.
Type of dengue: All cases (N=136) included in the study were serologically 
proven dengue cases. Out of this 
100 children (73.5%) had secondary dengue (table 3).
 
     Table 3:  Distribution of the type of Dengue infection
Type of Dengue 
Primary infection
Secondary infection
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36 children (26.4%) had primary dengue and 
 
 
   No :     Total 
   36 36/136 (26.4%) 
   100 100/136 (73.5%) 
Female
9
40
Normal
Elevated
 Figure 1: Distribution of the type of Dengue infection.
Table 4: Association of ALT values with Types of Infection
 
ALT value 
Normal 
40 - 100 
>100 
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 Figure 2: Association of ALT values with Types of Infection.
In the Table 4, the group with normal ALT values had 9 cases of primary 
dengue (23.6%) and 29 cases (76.3%) of secondary dengue. There were 12 
cases (21.4%) of primary dengue and 44 cases (78%) of secondary dengue in 
the group with ALT levels between 40 to100. In the gro
>100 there were 18 (42.8%) primary dengue and 24 (57.2%) secondary dengue 
cases.  
Among the 136 children, 98 had elevated ALT levels while in the 
remaining 38 children ALT value was normal (Table 5).
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    Table 5: Shows percentage of children with and without hepatitis.
 
ALT Level
Normal ALT
Elevated ALT
Total 
Figure 5: Shows percentage of children with and without hepatitis.
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 Number Percentage % 
 38 27.9 % 
 98 72.1% 
136 100 %  
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 Among these 98 children, 56 had SGPT 
while 42 had values above 100 IU/L (Table 6).
            Table 6: Distribution of ALT values in the study population
 
ALT levels
Normal
ALT 40 
ALT > 
 
Figure 6: Distribution of ALT values in the study population
 
Hepatomegaly distribution: 
seen in all children with elevated ALT levels. A few children with normal ALT 
levels did not have any liver palpable below the right coastal margin. The mean 
Normal 40
38
39 
between 40 IU/L and 100 IU/L, 
 
 
No : % within the study population 
 38 38/136 (28%) 
- 100 56 56/136 (41%) 
100 42 42/136 (31%) 
Palpable liver below the right coastal margin was 
-100 >100
56
42
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value of palpable liver in the groups with normal ALT, ALT 40-100 and ALT 
<100 are 2.0526, 3.2500 and 3.7143 respectively. Children with ALT> 100 had 
the highest mean palpable liver and those with normal ALT had the lowest 
mean palpable liver. (table 7) 
Table 7: Shows hepatomegaly in different ALT groups. 
 
  ALT values No of children Mean of palpable liver         F 
   value 
    P 
value 
Normal ALT  38 2.0526  
19.379 
 
P<0.01 ALT 40-100 56 3.2500 
ALT > 100 42 3.7143 
Total 136 3.0588 
 
In the above table F =19.379 
For the mean difference in hepatomegaly between groups [ALT 40 -100, control 
group and ALT > 100] is significant. (P < .01) 
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Post Hoc tests 
Table 8 
Comparison of palpable liver size 
among the study group  
 
    P value 
ALT Normal Vs ALT 40-100 
ALT Normal Vs ALT >100 
ALT 40- 100 Vs ALT > 100 
   <0.01 
  <0.01 
   0.184 
 
Further the post Hoc analysis (table 8) reveal that there is a significant 
association in palpable liver size between the groups with normal ALT and 
those with elevated ALT. Comparison of groups with normal ALT and ALT 
between 40 –100 is very significant (p < 0.01) which is similar to the significant 
association comparing the normal ALT group with ALT >100 (p < 0.01). 
However there is no significant association in hepatomegaly in the comparison 
between the study groups. P = .184 
PT Profile: All the 38 children with normal ALT also had normal PT. However 
8 out of 32 children (19%) with ALT > 100 IU/L had prolonged PT (p value 
0.005). Only 4 of 56 children (7%) with ALT between 40 and 100 IU/L had 
prolonged PT. (table 9) 
 
 
 
 Table 9: ALT levels & its association with PT 
 
 
Figure 3: ALT levels & its association with PT
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APTT Profile: Among the 38 children with normal ALT, only 3 (8%) had 
prolonged APTT, compared to 31 out of 98 children (31.6%) with elevated ALT 
( p value < 0.05). While only 11 out of 56 (19.6%) in the ALT 40 – 100 IU/L 
group had prolonged APTT, 20 out of 42(47%) in the > 100 ALT group had 
prolonged APTT (p value < 0.05).(table 10) 
Table 10: ALT levels & its association with APTT 
 
 
ALT levels 
Normal 
APTT 
Normal 
APTT  % 
Abnormal 
APTT 
Abnormal 
APTT  % 
Normal  35 35/38 (92%) 3 3/38 (7.9%) 
<100 45 45/56 (80%) 11 11/56 (20%) 
>100 22 22/42 (53%) 20 20/42 (47%) 
Total   102   102/136(75%)          34    34/136(25%) 
 Figure 4: ALT levels & its association with APTT.
Platelet drop distribution:  
mean value of each individual group was calculated. The mean value of 
platelets in the normal group, ALT 40 
46196.43 and 35000.00 respectively. The normal ALT group had the highest 
mean value whereas the group with ALT>100
(Table 11) 
Table 11: shows mean platelet value in different ALT groups.
  ALT values   No of children 
Normal ALT         
ALT 40-100        
ALT > 100         
Total        
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Platelet drop was seen in all the three groups. The 
– 100 and ALT > 40 were 70447.37, 
 had the lowest mean value. 
 Mean platelet value 
 38        70447.37 
 56        46196.43 
42        35000.00 
136        49514.71 
Abnormal APTT
3
11
20
NORMAL
<100
>100
 
 
     F 
 Value 
      P 
  value 
 
 
 
15.037 
 
 
 
<0.01 
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In the above table the F = 15.037. For the mean difference in platelet drop 
between groups [ALT < 100, control group and ALT > 100] is significant. 
(P<0.01) 
 
Table 12: Post Hoc tests. Comparative significance of mean platelet count 
among the study group 
 
Comparison 
 
P value 
ALT Normal Vs ALT 40-100 
ALT Normal Vs ALT >100 
ALT 40- 100 Vs ALT > 100 
<0.01 
<0.01 
0.181 
 
Further the post Hoc analysis (table 12) reveal that the there is a 
significant difference in the platelet drop when we compare the group with 
elevated ALT and the group with normal ALT levels. Comparison of groups 
with normal ALT and ALT between 40 –100 is very significant (p<0.01) which 
is similar to the significant association comparing the normal ALT group with 
ALT >100 (p<0.01). There is no significant association in platelet drop in the 
comparison within the groups with elevated ALT. (P = .181) 
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Table 13 
 
 
Platelet value 
                   ALT  
       Total Normal ALT40-
100 
ALT>100 
< 10,000       0      3      6          9 
10,000-20,000       4      5      9         18 
Above 20,000      34     48     27         109 
    Total       56     56     42         136 
 
In the above table 13 we can see the extent of platelet drop in each group. 
Platelet values below 10,000 were predominantly seen in the children with ALT 
>100. In the group with ALT > 100 six children had platelet below 10,000;9 
children with platelet value between 10,000 – 20,000 and 27 children with 
platelets above 20,000. Out of 56 children in the group with ALT 40- 100; 3 
children had platelet value below 10,000, 5 had between 10,000-20,000 and 48 
children with more than 20,000. Majority of the children (34) in the normal 
ALT level had platelet value more than 20,000 whereas only 4 had platelet 
between 10,000 -20,000 and none of the children had it below 10,000. 
Complication:  Only 2 children out of 38(5.3%) developed complications in 
comparison to 28 out of 56 (50%) children in group with ALT<100(P=.000) and 
34 out of 42 (81%) children in the group with ALT>100(p=.000).The 
comparison within the groups ALT 40- 100 and ALT >100 is also significant 
 (p=.002).[table 14]. The common complications seen were hypotension, 
bleeding manifestations, shock and plasma leakage.
Table 14: ALT levels & its association 
ALT value Complications (%)
normal 
< 100 
>100 
Total 64/136(47%)
 
Figure 5: ALT levels & its association 
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 Platelet transfusions: In the group of 38 children with normal ALT levels none 
received any platelet transfusion while compared to the 32 out of
(32.65%) with elevated ALT who received transfusion (p =.006). 23 out of 42 
(55%) children in the group with ALT >100 received transfusions when 
compared to 9 out of 56(16%) children in the group with ALT between 40 and 
100. (table 15) 
Table 15: ALT levels association in Platelet transfusion  
ALT levels 
Normal     
<100   9/56 (16%)
>100   23/42 (55%)
Total 32/136 (23.5%)
 
Figure 10: ALT levels association in Platelet transfusion.
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     104(76.5%)
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In majority of the cases platelet transfusions were given in cases of 
bleeding manifestations but for a few exceptions, where the transfusions were 
given prophylactically. Hence their significance of association was not 
calculated statistically. 
FFP transfusion: The normal ALT group with 38 children received no FFP 
transfusion while compared to 9 out of 98 children in the group with elevated 
ALT levels(p=.053). 8 out of 42 children (19%) in the group with ALT> 100 
received FFP transfusion while only one child out of 55(1.78%) in the group 
with ALT <100 received transfusion. (Table 16) 
Table 16: ALT levels association in FFP transfusion.   
ALT Values 
 
Transfused (%) 
  
Not Transfused 
Normal 0% 38 (100%) 
< 100 1/56 (1.8%) 55 (98.2%) 
> 100 8/42 (19.04%) 34 (80.9%) 
Total 9/136 (6.6%) 127 (93.4%) 
 
Again the indications for FFP transfusions was not standardised and their 
association of significance was no calculated statistically. 
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Hospital stay duration distribution:  The duration of hospital stay varied from 
group to group. The maximum period of hospital stay seen was 15 days and the 
minimum was 3 days. The mean of hospital stay duration was calculated and it 
was found that the mean of groups with normal ALT, ALT 40-100 and 
ALT>100 were 4.8421, 5.1250 and 6.2619 respectively. The mean of hospital 
stay was seen to be higher in children with ALT>100 when compared to the 
other two groups. (Table 17) 
Table 17 
  ALT values   No of children  Mean of Hospital stay     F 
VALUE 
    P 
VALUE 
Normal ALT          38          4.8421  
 
 
 
9.84 
 
 
 
 
<0.01 
ALT 40-100         56          5.1250 
ALT > 100         42          6.2619 
Total         136          5.3971 
 
In the above table F = 9.843 
For the mean difference in duration of hospital stay between groups [ALT < 
100, control group and ALT > 100] is significant. (P <0.01) 
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Table 18: Post Hoc tests. Comparative association in hospital stay duration 
among the groups. 
Comparative groups      P value 
ALT Normal Vs ALT 40-100 
ALT Normal Vs ALT >100 
ALT 40- 100 Vs ALT > 100 
   0.686 
  <0.01 
  <.01 
 
Further the post Hoc analysis (table 19) reveal that there is a significant 
difference in the duration of hospital stay in children with SGPT > 100 when 
compared to the other two groups. . Comparison of groups with ALT>100 and 
ALT between 40 –100 is very significant (p=.002) which is similar to the 
significant association comparing the normal ALT group with ALT 
>100(p=.000).However There seems to be no significant association between 
the groups with normal ALT level and the group with ALT 40-100. (p=.686) 
Table 20: shows distribution of hospital stay in correlation with ALT value 
                         HOSPITAL STAY 
ALT Level    ≤ 5 Days     6 – 9 Days  ≥ 10 Days 
Normal ALT  30/38 (79%) 8/38 (21%)       - 
ALT 40-100  35/56 (62.5%) 21/56 (37.5%)        - 
ALT > 100 16/42 (38%) 24/42 (57%) 2/42 (4.8%) 
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Table 20 above shows the distribution of duration of hospital stay of all the 136 
children. Out of the 38 children with normal ALT levels, 30 children (79%) 
stayed in hospital ≤5 days and only 8 children (21%) stayed more than 5 days. 
where as in the group with ALT 40 -100 with 56 children, 35 (62.5%)stayed in 
hospital ≤5 and 21 children (37.5%) stayed longer than 5 days. In the group 
with ALT>100 with 42 children, 16(38%) of them stayed ≤5 days and 24 
children (57%) stayed more than 5 days. This is the only group where 2 (4.8%) 
children stayed longer than 10 days. 
Figure 11: shows distribution of hospital stay in correlation with ALT 
value 
 
Duration of PICU stay:  Children who were admitted sick or developed 
complications in the ward were kept in PICU. The mean PICU stay was 
calculated for all the 3 groups. The mean of duration in PICU stay of children 
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with control group, SGPT < 100 and SGPT > 100 were 0 .1053, 1.4286 and 
3.0476 respectively. Children with ALT levels more than 100 were seen to have 
the highest mean for PICU stay duration. (table 21) 
 Table 21: Mean hospital stay in children in relation with ALT levels. 
 
  ALT values   No of children  Mean of PICU stay     F 
value 
     P 
value 
Normal ALT          38          .1053  
 
 
 
33.390 
 
 
 
 
P<0.01 
ALT 40-100         56          1.4286 
ALT > 100         42          3.0476 
Total         136          1.5588 
 
In the above table F = 33.390 
For the mean difference in duration of stay in PICU between groups [ALT < 
100, control group and ALT > 100] is significant. (P < 0.01) 
Table 22: Post Hoc tests. Comparative association in PICU stay duration 
among the groups. 
Comparative groups  P value 
ALT Normal Vs ALT 40-100 
     ALT Normal Vs ALT >100 
     ALT 40- 100 Vs ALT > 100 
< 0.01 
<0.01 
<0.01 
 
Further the post Hoc analysis (table 22) reveals that there is a significant 
association in PICU stay duration between all the 3 groups. 
     
 Table 23: Distribution of PICU stay duration in relation to ALT levels.
 
PICU stay     NIL  
Normal ALT  36/38 (95%)
ALT 40-100 27/56 (48.2%)
ALT > 100 7/42 (16.6%)
Figure 12: Distribution of PICU stay duration in relation to ALT levels.
     Table 23 above shows the distribution of children who stayed in the PICU. 
In the total study group of 136 children only 66 children (48.5%) stayed in 
PICU. In 38 children with normal ALT only 2 children had to stay in PICU and 
that too for ≤ 5 days. Out of 56 children with ALT 40
children stayed in the PICU in which 26 children (46.4%) stayed 
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children (5.3%) stayed for more than 5 days. It is only in the group with 
ALT>100 where one child stayed longer than 10 days. Out of 42 children in this 
group 31 children (73.8%) stayed less ≤ 5 days and 3 (7.1%) of them stayed 
more than 5 days. 
Repeat ALT values: time taken to recover-    Majority of the children with 
elevated ALT values returned to normal within 2 weeks. In the group with ALT 
40 – 100,the ALT values returned to normal in all the 56 children where as 5 
out of 42 (5%) children in the group with ALT>100 took more than 2 weeks 
and the remaining 37 children in less than 2 weeks. (Table 24) 95% of the 
elevated ALT values returned to normal in 2 weeks. 
Table 24: Time duration for normalisation of ALT values 
Time taken for ALT to normalise ALT <100 ALT>100 Total 
Less than 2 weeks 56 37 93/98 (95%) 
More than 2 weeks 0 5 5/98 (5%) 
 
56 42 98 
 
 
 
 
 Figure 13: Time duration
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DISCUSSION 
 
Dengue is prevalent worldwide and numerous studies are done across the 
globe. Majority of the literature is available from the developing countries of 
South East Asia. In this study we aim to study the incidence and degree of 
hepatic dysfunction in children less than 15 yrs admitted with serologically 
proven dengue infection. 
Type of dengue:  Out of the total 136 children with serologically proven 
dengue, 100 cases were found to be secondary dengue (73.5%) and remaining 
36 were primary (26.5%). In the study done at Apollo hospital, Chennai, Fifty-
one children (46.7%) had primary dengue infection and 45 (41.2%) had 
secondary dengue infection (48). Of the children with elevated ALT, 27 
children had primary dengue infection (27.6%) and 71 children had secondary 
dengue (72.4%) whereas in the group with normal ALT, 9 were primary dengue 
infection (23.7%) and 29 children had secondary dengue infection (76.3%). 
From our data, we have seen a predominance of secondary dengue over primary 
dengue though it is statistically not significant. The reason for the predominance 
in secondary dengue infection is that many of the children live in dengue 
endemic areas and there is a high chance that they have been exposed to dengue 
earlier. 
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Percentage of hepatitis:   In our study with 136 consecutive serologically 
proven dengue cases, 98(72.1%) children developed hepatitis as evidenced by 
elevated ALT levels. Mohan et al in 2000 found 96% of children in his study to 
have elevated transaminase level (49). 
Age distribution:  All age groups were equally affected. However hepatic 
involvement was more predominant in children aged less than one year. 
Suchithra Ranjith et al, in her study states that severe disease occurred most 
often in infants followed by the 1–5 year age group (48). 
 Out of the 20 children aged less than 1yr included in the study, 17 had elevated 
SGPT levels (85%). Children aged more than 10 were seen to be affected 
slightly lesser when compared to the other age groups. Statistically the 
association between age and elevation of SGPT was found to be insignificant. 
(p= .160) 
Sex distribution: In the consecutive 136 children, 87(64%) were boys and 49 
were girls (36%). The group with elevated ALT had 59.19% boys and 40.81% 
girls whereas the normal ALT group had 76.31% boys and 33.69% girls. There 
was no statistically significant finding either in the incidence of dengue or 
elevation of ALT based on the sex of the child. Similar results were seen in the 
study from Chennai done in Apollo hospitals where there was no sex 
predilection (48). 
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Coagulation profiles: Both PT and APTT were evaluated for all the patients.  
PT: Only 12 children had abnormal PT values. None of the children in the 
normal ALT group had abnormal PT values. We found 18% of the total study 
population with prolonged PT. In a study from Mysore, Kalenahalli 
Jagadishkumar et al found prolonged PT in 20% of children with Dengue 
infection which is similar to our result (50). Study done by Suchitra Ranjith in 
2006 shows disordered coagulation (prolongation of the prothrombin and/or 
partial thromboplastin time) was seen in 74 children (67.8%)(48). Out of the 12 
children with abnormal PT values, 8 children had ALT >100 whereas the other 
group with ALT < 100 had 4 children. Our study shows that children with 
elevated ALT levels are at a higher risk of developing prolonged prothrombin 
time and thereby bleeding when compared to children with normal ALT levels. 
However there is no significant association seen within the groups with elevated 
ALT levels. 
APTT: In the group with elevated ALT levels 31 children (31.63%) had 
abnormal APTT levels. 64.51% of the children with abnormal APTT levels 
belonged to the group with ALT>100. In the normal ALT group only 3 children 
had prolonged APTT. From the study it is seen that prolonged APTT is 
predominantly seen in children with elevated ALT levels when compared to the 
children with normal ALT value. It was also found that ALT values correlated 
with the elevation of APTT. There was a rise in APTT value as there is a rise in 
ALT level.   
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Platelet drop: Out of 9 children with platelet value < 10,000, 66.6% had 
ALT>100. In those children with platelet value between 10,000 and 20,000, 
62.48% had ALT >100. In the 136 children 19.8% had platelet value below 
20,000 which is quite similar to the study done by Gurudeep S.Dhooria (51). 
Platelet counts less than 50,000/cumm was noted in 62.3% in the study done by 
Suchitra Ranjith (48).  In the control group 89.47% had platelet value >20,000. 
There is a statistically significant association between drop in platelet count 
while comparing normal ALT group and the group with ALT<100 (p<0.01). 
Similarly the association is significant comparing normal ALT group with the 
ALT >100 group (p<0.01). Within the ALT elevated groups there has been no 
significant association in platelet drop (p=0.181). The study shows that children 
with elevated ALT levels are at a higher risk of developing thrombocytopenia 
when compared to those with normal ALT value. However the degree of ALT 
elevation has got no correlation with the fall of platelets. 
Hepatomegaly: Hepatomegaly was clinically observed in all the children in the 
study group. In the total of 136 children, 91% had hepatomegaly which is 
similar to the study done by Kalenahalli Jagadishkumar et al in Mysore which 
showed hepatomegaly of 96% (50). Petddachai and Faridi et al reported 
hepatomegaly in all children with severe dengue (4, 16). In the elevated ALT 
group, 15 children had hepatomegaly (4cm liver palpable below the right 
coastal margin) against only one child in the normal ALT group. In the normal 
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ALT group 28.94% of children did not have hepatomegaly. Statistical analysis 
has shown that the mean difference in hepatomegaly between the normal and 
elevated ALT group is significant (p<0.01). There seems to be no statistical 
significance in mean difference in hepatomegaly within the groups with 
elevated ALT (p=.184). The study shows that there is an increase in the liver 
size as the ALT value is elevated but the level of ALT elevation has no 
significant correlation with the palpable liver size.  
Complications: Complications were seen in all the 3 groups. Complications 
were very minimal in the control group. The common complications seen were 
hypotension, bleeding manifestation, shock and plasma leakage. Only 2 out of 
38 children (5.26%) in the control group developed complications where as 
62/98 children in the study group (63.26%) developed complications. There 
seems to be a significant association in complications comparing control group 
with the study group (p<0.01) and also within the study groups (p<0.01). The 
study shows that complications occur more frequently when the level of ALT is 
very high. There was an increasing trend to develop complications as and when 
the ALT values were rising. 
Platelet transfusion: In majority of cases, platelets were transfused when 
children developed bleeding manifestations. In few children, prophylactic 
transfusion was carried out as decided by the treating unit. A total of 32 children 
received transfusions. Only 2 out of the 32 children had normal ALT. In the 
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study group with ALT>100 there were 8 children who received more than 2 
transfusions. Statistical correlation was not done because on few instances 
prophylactic transfusions were also given. However it could be concluded from 
the study that the necessity of transfusion is on the higher side for children with 
elevated ALT levels. 
FFP transfusions: None of the children in the control group received 
transfusions. In the elevated ALT group 9 children received FFP transfusions. 
Out of the 9 children 88.88 % had ALT> 100. No statistical analysis was done 
because the indication for FFP transfusion was not standardised. Then again the 
study shows that majority of the transfusion was given for children with very 
high ALT value. 
Duration of hospital stay: The minimal duration of hospital stay was 3 days 
and the maximum duration was 15 days. In the elevated ALT group 51 out of 98 
(52.04%) children stayed up to 5 days and 45/98 (45.91%) stayed more than 5 
days. Only 2 children in the study group stayed longer than 10 days. In the 
control group 30/38 children (78.94%) stayed up to 5 days and only 8/38 
children (21.05%) stayed longer than 5 days. None stayed more than 10 days. 
There is a significant association in the mean duration of hospital stay between 
the study group ALT>100 and the other two groups (p<0.01). We infer from the 
study that children with normal ALT values and those with mild elevation in 
ALT do not have much difference in their duration of hospital stay. However 
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Children with higher ALT values tend to stay for longer period of time in the 
hospital when compared to those with normal and mild elevation of ALT. 
PICU stay: A total of 66 children stayed in PICU from all the 3 groups. From 
the normal ALT group there were only 2 of them (5.26%) and both of them 
stayed less than 5 days. Among the elevated ALT group 64/98 (65.30%) stayed 
in PICU. In this 64; 57 children stayed up to 5 days (89.06%) and only 6 of 
them stayed longer than 5 days. Only one child in the whole study stayed longer 
than10 days in PICU. Statistical analysis reveal that there is a significant 
association in the duration of stay in PICU between all the 3 groups (p<0.01). 
Study shows that children with very high values tend to stay longer in the PICU 
than the other 2 groups. Children with mild elevation of ALT values also stay 
longer than those with normal ALT value. 
Time taken for normalisation of ALT: Majority of the children with elevated 
ALT values returned to normal within 2 weeks. In the group with ALT 40 – 
100, the ALT values returned to normal in all the 56 children where as 5 out of 
42 (5%) children in the group with ALT>100 took more than 2 weeks and the 
remaining 37 children in less than 2 weeks. All the 5 children’s ALT values had 
normalised when the test was repeated at one month. In all 98 children with 
raised liver enzymes, Hepatitis A, Hepatitis B and Hepatitis E were excluded by 
appropriate investigations. None of the children developed clinical jaundice and 
none developed fulminant hepatic failure. 
64 
 
CONCLUSION 
1. 72.1% of children in the study population developed hepatitis. 
2. Prolonged APTT is predominantly seen in children with elevated ALT 
levels. 
3. Children with elevated ALT levels are at a higher risk of developing 
prolonged prothrombin time. 
4. Children with elevated ALT levels are at a higher risk of developing 
thrombocytopenia; however the degree of ALT elevation has got no 
correlation with the fall of platelets. 
5. There was an increasing trend to develop complications as and when the 
ALT values were rising. 
6. The study shows that majority of the transfusion was given for children with 
high ALT value. 
7. Children with normal ALT values and those with mild elevation in ALT do 
not have much difference in their duration of hospital stay however children 
with ALT values more than 100 tend to stay for longer period of time in the 
hospital. 
8. Children with very high values tend to stay longer in the PICU. 
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9. Every child with hepatitis because of Dengue infection normalised their ALT 
value in less than one month. 
10. None of the children developed clinical jaundice and none developed 
fulminant hepatic failure. 
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ABBREVATIONS 
DF        - DENGUE FEVER 
DHF    - DENGUE HEMORRHAGIC FEVER 
DSS    - DENGUE SHOCK SYNDROME 
AE    - AEDES 
WHO    - WORLD HEALTH ORGANISATION 
DEN 1, 2, 3 & 4  - DENGUE VIRUS SEROTYPES 1, 2, 3 AND 4 
IgG, IgM   - IMMUNOGLOBULIN G AND M 
ELISA   - ENZYME LINKED IMMUNOSORBENT ASSAY 
PCR     - POLYMERASE CHAIN REACTION 
Hb    - HEMOGLOBIN 
PCV    - PACKED CELL VOLUME 
SGPT  -SERUM GLUTAMATE OXALO-ACETATE 
 TRANSAMINASE     
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SGOT -SERUM GLUTAMATE PYRUVATE                                              
TRANSAMINASE 
FFP    - FRESH FROZEN PLASMA 
ALT     - ALANINE AMINO TRANSFERASES 
PICU    - PAEDIATRIC INTENSIVE CARE UNIT 
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PROFORMA 
NAME :    AGE:   SEX:   UNIT: 
OP NO:    DOA:   DOD:                WEIGHT: 
 
CLINICAL FEATURES YES NO 
IRRITABILITY   
ERYTHEMA   
PETICHIAE   
MALENA   
OTHER BLEEDING MANIFESTATIONS   
COLD EXTREMITIES   
PUFFINESS OF FACE   
ASCITES   
HEPATOMEGALY   
PLEURAL EFFUSION   
JAUNDIC   
ENCEPHALOPATHY   
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LABORATORY DATA 
DAY OF STAY:     
TOTAL COUNT 
    
DC 
    
PCV 
    
HB 
    
PLATELT COUNT 
    
ESR 
    
PERIPHERAL 
SMEAR 
    
PT 
    
APTT 
    
SGPT 
    
XRAY CHEST 
    
 
DENGUE SEROLOGY POSITIVE NEGATIVE 
IgM 
  
IgG 
  
 
  
 
 
 
S.NO NAME                              IP NO A S SG PL PT AP LS T RS D C D H PS 
1. SHIFANA                         I11017867 5Y F 62 38000 13.6 38 3 2 P 19 2 + 4 2 
2. SIVA SANKARI                I11018062 10Y F 68 48000 12.8 41.8 2 - 27 2 - 6 - 
3. HARI.P                             I11018067 10Y M 219 9000 14.9 46.1 8 2 F 38 2 + 5 3 
4. ANTO.M                          I11018075 7Y M 490 14000 13.5 43.5 5 2 P 54 2 + 5 3 
5. BRINDHA                         I11019022 9Y F 129 8000 15 39.3 5 2 P 34 2 + 8 3 
6. GOWTHAM                     I11019348 8Y M 64 18000 19.2 47.2 5 4 P 24 2 + 7 5 
7. BHARTHINI                      I11019706 6Y F 48 5000 13.8 40.1 4 2 P 18 2 + 7 5 
8. DAVID                               I11019961 9Y M 95 91000 12.7 32.3 3 - 32 2 - 5 - 
9. SITHARTHAN                   I11020135 10Y M 94 35000 11.8 33.4 3 - 28 2 + 4 - 
10 BOOVESH                        I11020317 7 M M 49 97000 12.6 31.4 3 - 24 1 - 6 - 
11 VENKADESH                    I11020328 4Y M 122 35000 13.8 52.7 3 - 32 2 + 9 4 
12 SAHANA                           I11021486 8M F 1348 22000 31.9 76.7 4 4P&2F 81 1 + 15 11 
13 VARSHA.SRE                    I11022635 3Y F 350 4000 37.4 91.1 4 2 P 36 2 + 5 3 
14 MOUNISH                        I11022919 8M M 594 24000 16.3 67.3 5 4P&IF 38 2 + 10 9 
15 MADHU.P                         I11023643 9Y M 55 7000 13.5 32.4 7 2 P 18 2 + 5 3 
16 VISHWANTH                    I11024589 14Y M 62 30000 14.5 37.6 3 - 28 2 + 4 2 
17 AISWARYA.R                    I11024989 4Y F 67 26000 12.8 42.6 3 - 31 2 + 5 4 
18 NAGA GAYATHRI             I11025185 12Y F 59 60000 13.3 33.5 3 - 24 1 + 5 4 
19 SACHIN                             I11025509 9M M 156 60000 13.2 37.3 3 - 34 1 _ 5 - 
20 AISWARYA.S                    I11025669 11Y F 168 21000 14.9 48.2 3 - 29 2 + 5 2 
  
 
S.NO NAME                                        IP NO A S SG PL PT AP H T RS T C D
I
H 
P
S 
21 UTESH                                I11027020 7Y M 230 15000 16.2 39.2 4 1 P 31 2 + 8 3 
22 DEVADARSHINI 13Y F 81 31000 13.6 36.7 3 - 30 2 - 4 - 
23 SOWMIA                            I11027777 12Y F 45 72000 12.4 30.6 3 - 28 2 - 6 - 
24 TAMILARASI                      I11028120 9Y F 260 24000 13.4 44.8 4 - 30 2 + 5 4 
25 NAGA DEVI                        I11028178 11Y  F 65 59000 13.1 31.2 4 2 P 27 2 + 4 2 
26 DHAKSHAN                        I11028304 2Y M 339 50000 14.5 56 3 - 38 1 - 8 3 
27 ASHWIN                             I11028862 14Y M 65 76000 12.8 30.6 2 - 23 2 - 4 - 
28 DEEPAHARI                        I11028862 4Y M 88 30000 12.4 39.2 3 - 31 1 + 6 4 
29 AKSHATHA                         I11029359 7M F 325 18000 12.7 39.2 3 2 P 34 1 + 9 4 
30 SANDEEP                            I11029826 10M M 144 30000 12.4 38.3 4 - 28 1 + 6 4 
31 SHRI MANGAI                    I11031653 8Y F 66 79000 12.5 41.2 3 - 29 2 + 5 3 
32 THARUN                             I11033038 10M M 623 60000 13.3 52.1 6 1P&2F 34 1 + 9 7 
33 KEERTHANA                       I11033216 6Y F 142 93000 13 30.8 5 - 32 1 - 6 - 
34 NAVIYA                               I11033804 3Y F 309 36000 12.5 30.3 3 2 P 33 2 + 5 2 
35 SUBHASREE                        I11034230 2Y F 270 14000 13 45.4 3 4 P 44 2 + 6 4 
36 SURUTHIKA                        I11034454 7Y F 148 17000 13.7 43.5 3 2 P 38 2 + 7 4 
37 NAVNEETHAN                   I11035056 8Y M 89 19000 12.8 37 3 - 32 2 + 6 3 
38 BHOOMIKA                        I11035175 5Y F 75 28000 12 28.9 3 - 32 1 + 3 2 
39 NITESH                                I11035192 1Y M 104 98000 12.8 30.4 4 - 22 1 - 6 - 
40 JEEVANANTHM                 I11035296 13Y M 130 16000 13.1 38.7 3 3P&1F 34 2 + 6 3 
 
 
  
 
S.NO NAME   A S SG PL PT AP L
S 
T RS T C D P
S 
41 SHAMEESHA                     I11035449 5M F 68 37000 19 45.9 3 2P&1
F 
22 1 + 9 4 
42 LOKESH                              I11035635 7Y M 54 86000 13.2 30.2 5 - 29 2 - 4 - 
43 SANKARA.N                       I11036184 12Y M 122 7000 12.5 37.4 6 3 P 37 2 + 6 4 
44 MUGESH                            I11036304 2Y M 51 23000 11.9 37.6 3 - 27 2 + 5 1 
45 KARTHIKEYAN                   I12000806 10Y M 134 10000 14.1 40.1 3 5 P 37 2 + 7 4 
46 SHYAM                               I12000849 6Y M 85 36000 13 33.1 2 - 27 2 + 5 2 
47 SIMIKA                               I12001275 7Y F 56 55000 11.9 34.6 2 - 31 2 - 4 - 
48 SARATH                              I12001363 11Y M 124 9000 13.6 34.3 4 2 P 32 2 + 6 3 
49 YOGESHWAR                     I12001368 8Y M 47 40000 13.2 31.2 3 - 28 2 + 6 2 
50 ABISH                                  I12001841 4Y M 68 21000 13.6 34.2 4 - 28 2 + 6 3 
51 SUDHAN                             I12001864 12Y M 131 88000 12.4 29.4 3 - 45 2 + 5 3 
52 DEVI PRASATH                   I12001939 11 M M 85 28000 12 46.3 5 - 35 2 + 9 5 
53 DHARSHINI.P                     I12002187 4Y F 76 16000 13.2 31.6 3 - 32 2 + 6 3 
54 ASHWITHA                         I12002408 14Y F 219 22000 15.3 35.2 3 1 P 34 2 + 7 3 
55 PAVITHRA                           I12002977 8Y F 44 10000 12.6 39.6 5 2 P 28 2 + 5 2 
56 SANTHANA                         I12014321 11Y M 325 38000 13.4 44.4 4 - 34 2 + 7 3 
57 KISHORE                             I12014983 8Y M 80 44000 12.3 33.7 2 - 31 2 + 6 2 
58 AMIR                                   I12009346 5Y M 42 25000 14 36.5 4 - 30 2 - 6 - 
59 VARSHASHRI                      I12009568 6Y F 59 45000 12 27.9 3 - 22 2 - 6 - 
 
 
  
 
 
S.NO NAME   A S SG PL PT AP L
S 
T RS T C D PS 
60 DIVAHAR                            I12009805 7Y M 64 60000 12.9 30.1 3 - 28 2 - 4 - 
61 DHARNISH                         I12011582 4M M 258 28000 12.8 40 3 3P&2F 36 1 + 7 5 
62 LOGESH                              I12013550 10Y M 53 62000 12.7 30.7 4 - 27 2 - 6 - 
63 VISHANTH                          I12013759 5Y M 52 96000 12.3 31 5 - 26 2 - 4 - 
64 DEEPAK .S                          I12015134 14Y M 48 81000 12.7 30.3 2 - 22 2 - 5 - 
65 SHAHANA                          I12015493 4M F 851 32000 26.7 66.5 4 3P&2F 56 1 + 5 - 
66 SABARIWASAN                 I12015747 12Y M 56 94000 12.8 30.3 2 - 28 2 - 5 - 
67 KOKILA B%                         I12015912 8M M 52 51000 15.5 51.0 4 - 31 1 + 6 - 
68 PRAKASH                           I12016826 4Y  M 81 40000 12.9 41.4 3 - 37 2 + 6 2 
69 ARISUDHAN                      I12018753 11Y M 85 45000 12.8 31.4 3 - 31 2 - 6 - 
70 SREE VANSHIKA               I12018939 11M F 339 22000 13.8 38.5 4 1 P 35 1 + 6 4 
71 BHUVANSWARI                I12019211 13Y F 95 29000 13.3 34.5 3 4 P 33 2 + 5 3 
72 MEGAVARSHNI                I12019626 3Y F 128 15000 13.4 36.3 4 - 34 1 + 6 3 
73 LOHIT                                 I12019944 9Y M 152 53000 12.9 29.5 2 - 28 2 + 4 - 
74 SAI PRAVEEN                    I12024546 9M M 105 30000 13.5 44.9 3 - 36 1 - 6 2 
75 KIRUTHIKA                        I12019952 8Y F 48 52000 13.4 37.2 3 - 26 2 - 5 - 
76 GAYATHRI                         I12020263 11Y F 61 16000 13.1 34.5 3 - 33 2 - 5 - 
77 AMBRITHA                        I12020383 12Y F 51 30000 12.9 43.1 2 - 22 2 + 5 1 
78 KAMALESH                        I2025688 11M M 87 54000 13.8 36.5 4 - 30 1 - 6 2 
79 PRIYANKA                         I12021146 11Y F 87 59000 13.1 33.4 4 - 31 2 - 3 - 
 
  
 
 
S.NO NAME   A S SG PL PT AP LS T RS T C D PS 
80 SUDHARSHAN                  I12021998 2Y M 221 42000 14.2 36.4 3 - 38 2 - 4 2 
81 YOGARAJ                           I12022479 9Y M 43 98000 12.8 31.4 2 - 17 1 - 4 - 
82 SANGMITHRA.C               I12026689 11M F 93 37000 11 29.0 2 - 24 1 - 5 2 
83 YASHWANTH                    I12022765  7Y M 92 28000 12.7 32.1 4 - 25 2 - 3 - 
84 GOWTHAM                       I12023336 11Y M 172 24000 19.5 56.7 5 3P&1F 33 2 + 5 3 
85 SANGAMITHRA                I12023439 7Y F 47 33000 12.8 34.7 3 - 22 2 - 6 2 
86 RAMYA                              I12023678 6Y F 68 13000 15.1 61.5 3 2 P 27 2 + 5 3 
87 AMRITA                             I12023917 7Y F 97 94000 12.6 29.4 2 - 19 1 - 3 - 
88 NITESH                               I12024682 12Y M 114 82000 13.0 31.4 3 - 34 2 - 3 - 
89 KOWSHIKA                        I12024704 6Y F 46 42000 12.5 29.5 2 - 18 2 - 4 - 
90 GOKUL.G                           I12024851 8Y M 122 64000 14.3 49.4 3 2 P 38 2 + 5 3 
91 PRIYADARSHNI                 I12025058 9Y F 118 62000 13.4 37.4 3 - 34 2 + 6 2 
92 GOKUL                               I12025077 10Y M 155 54000 12.2 33.7 2 - 37 1 - 3 - 
93 ARUN                                 I12025195 14Y M 102 18000 14.5 44.6 2 2 P 35 1 + 7 3 
94 CHIRANJEEV                     I12025367 3Y M 242 88000 13.8 38.4 3 - 29 1 + 4 2 
95 HARISH                              I12026338 5M M 56 50000 12.8 36.4 5 - 24 1 + 4 2 
96 SUJITHA                             I12026385               2Y F 138 14000 16.6 50.1 4 2 P 38 2 + 6 3 
97 THANIKAIVEL                    I12026679 10Y M 74 42000 13.2 34.5 3 - 33 2 - 5 - 
98 VIGNESH                            I12026558 13Y M 56 66000 12.8 30.8 4 - 28 2 - 4 - 
               
 
 
  
 
 
S NO  NAME A S SG PL PT AP LS T RS T C D PS 
1 SRIMATHI                        I11019478 9Y F 34 86000 13 31.2 3 - - 2 - 5 - 
2 KISHORE                          I11019479 1Y M 35 119000 11.4 29.4 2 - - 1 - 3 - 
3 AJAY KUMAR                  I11019630 6Y M 26 80000 13.8 36 2 - - 2 - 3 - 
4 DURAI                              I11019833 8Y M 22 44000 11.5 30.2 - - - 2 - 5 - 
5 DHARSHAN                     I11020422 7Y M 24 46000 12.4 32.5 2 - - 2 - 5 - 
6 DHANYA                          I11023848 4Y F 29 57000 12.8 35.1 2 - - 2 - 5 - 
 7 HAFRAAN                        I11024033 10M M 37 20000 12.3 42.5 4 - - 1 - 5 - 
8 DEEPA                              I11025292 10Y F 34 58000 14.4 21.9 3 - - 2 + 7 2 
9 SRINIVAS                         I11025758 4Y M 30 91000 11.8 30.8 2 - - 1 - 6 - 
10 MITHUN                          I11026389 6Y M 24 120000 - - - - - 1 - 5 - 
11 KAMAL                             I11027096 14Y M 35 50000 12.4 35.9 2 - - 2 - 6 - 
12 MONIKA                          I11027890 14Y F 24 23000 13.6 44.6 3 - - 2 - 5 - 
13 FAYAZ                              I11028483 14Y M 24 114000 - - - - - 1 - 6 - 
14 DHAKNESHWAR             I11028487 5Y M 36 23000 14.8 40.1 3 - - 2 - 6 - 
15 KEERTHIKA                      I11028503 12Y F 12 83000 12.7 32.5 - - - 1 - 4 - 
16 GOWTHAM                     I11028504 13Y M 26 77000 11.9 31.9 - - - 2 - 5 - 
17 JAMES                              I11028721 7Y M 11 84000 12.7 30.8 - - - 2 - 4 - 
18 SRI VISHNU                     I11033726 4Y M 28 86000 12.5 33.1 3 - - 1 - 4 - 
19 TAMILARASI                    I11034853 9Y M 25 38000 14.1 38.7 2 - - 2 - 4 - 
20 ASHWIN RAJ                    I12010632 3Y M 31 100000 11.5 34.9 - - - 2 - 5 - 
 
 
  
 
S NO NAME A S SG LP PT AP LS T R T C D PS 
21 BHUVNESHWRI                 I12011129 7Y F 34 67000 11.8 29.4 3 - - 2 - 5 - 
22 GOKUL.R                            I12014624 7Y M 32 110000 12.4 30.5 2 - - 2 - 3 - 
23 SRIVARSHAN                     I12015742 12Y M 18 64000 11.9 30 2 - - 2 - 5 - 
24 DEVASH.S                          I12015815 11Y M 38 96000 13 29.6 4 - - 2 - 4 - 
25 KAVIYA                               I12016246 3Y F 27 77000 12.9 26.4 3 - - 2 - 5 - 
26 ASHOK KUMAR                 I12016550 14Y M 30 38000 13 29.6 3 - - 2 - 4 - 
27 GLADIAS SHERIN              I12016715 12Y F 23 35000 12.6 28.4 3 - - 2 - 4 - 
28 ROHIT                                  4Y M 30 20000 11.8 29.4 4 - - 2 - 5 - 
29 PRABHAKARAN                I12020220 12Y M 28 30000 13.4 30.7 4 - - 2 - 5 - 
30 MITHUN                            I12020354 12Y M 15 113000 - - 2 - - 2 - 4 - 
31 RAJESH.R                          I12022249 14Y M 26 14000 13 29.6 - - - 2 - 8 - 
32 SAJITH                               I12022284 6Y M 31 75000 11.8 30.2 - - - 2 - 5 - 
33 THIRUPATHI                     I12022392 14Y M 16 145000 - - - - - 2 - 4 - 
34 MUKESH                           I12022588 11Y M 11 136000 - - - - - 2 - 7 - 
35 BHARANIDHRAN             I12022705 5Y M 25 82000 - - 4 - - 1 - 3 - 
36 RIFAYA                              I12022945 1Y F 25 16000   5 - - 1 - 7 - 
37 ABILASH                            I12022952 13Y M 21 135000 - - 2 - - 2 - 3 - 
38 SANTHOSH                       I12023317 14Y M 31 25000 12.3 33.2 4 - - 2 + 5 2 
               
               
 
